The FDA has approved Vykat XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years ...

Credit: Solano Therapeutics. Vykat XR contains an extended-release formulation of diazoxide choline, the crystalline salt of diazoxide. Vykat XR is expected to be available in April 2025.

Soleno Therapeutics has won US Food and Drug Administration (FDA) approval for diazoxide choline – which will be branded as Vykat XR – to treat extreme hunger in patients with Prader-Willi syndrome.

Vykat XR is specifically indicated to address hyperphagia, or the abnormally strong sensation of hunger, which often leads to excessive eating. Its approval covers both adult and pediatric patients ...

First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome. Management to host conference call and webcast today, March 26 th, at 5:30pm ET. REDWOOD C ...

The FDA has approved Soleno Therapeutics’ Vykat XR (diazoxide choline) extended-release tablets to treat hyperphagia in individuals aged four years and older with Prader-Willi syndrome (PWS). The ...

The FDA’s approval of VYKAT XR for the treatment of hyperphagia in patients with PWS came with a clean label and reasonable monitoring requirements. This outcome represents a best-case scenario for ...

Soleno Therapeutics, Inc., a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved ...

US FDA approves Soleno Therapeutics’ Vykat XR to treat hyperphagia in Prader-Willi syndrome: Redwood City, California Saturday, March 29, 2025, 18:00 Hrs [IST] Soleno Therapeuti ...

The US Food and Drug Administration (FDA) has approved Soleno Therapeutics’ Vykat XR (diazoxide choline) extended-release tablets as the first treatment to address hyperphagia in patients with the ...

The FDA’s approval of VYKAT XR for the treatment of hyperphagia in patients with PWS came with a clean label and reasonable monitoring requirements. This outcome represents a best-case scenario ...